Skip to main content
PKTX
OTC Life Sciences

ProtoKinetix Q1 Loss Narrows to $77,726 With $524 Cash; Going Concern Stands

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0
Mkt Cap
$123.639K
52W Low
$0
52W High
$0.015
52W Position info
200% above low
Off High info
98% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

PKTX has more than doubled off its 52-week low of $0 on light trading volume (0.1× avg).

Summary

ProtoKinetix's Q1 2026 10-Q shows a $77,726 net loss, $524 of cash and a repeat going-concern warning, funded only by penny-priced placements and convertible notes after the quarter.


Key Events · Earnings and Guidance · PKTX

  • Going Concern Doubt Reiterated

    Management states the company has not developed a commercially viable product and that losses since inception raise substantial doubt about its ability to continue as a going concern.

  • Cash Down to $524

    Cash fell to $524 at March 31, 2026 from $1,118 at December 31, 2025, and the working capital deficit widened to $235,879 from $183,266.

  • Q1 Loss Narrows to $77,726

    Net loss for the three months ended March 31, 2026 was $77,726 versus $97,690 a year earlier, with R&D down to $24,220 from $33,810.

  • Post-Quarter Penny Financings

    After the quarter the company raised $165,400 via convertible notes (16,540,000 shares at $0.01), $21,000 in an April 30, 2026 placement (2,100,000 shares at $0.01) and $117,900 in notes between July 29 and October 15, 2026 (11,790,000 shares at $0.01).


Analysis · PKTX · Life Sciences

ProtoKinetix ended March 31, 2026 with $524 of cash and a $235,879 working capital deficit, and management repeats that substantial doubt exists about the company's ability to continue as a going concern. Since then, the only funding has come from small $0.01-per-share private placements and convertible notes — roughly $304,300 combined across the April, June and July-October 2026 issuances — which keeps the lights on but adds tens of millions of shares at a penny. The company also disclosed that its disclosure controls and procedures are not effective and that a director resigned on March 31, 2026. The SightPath Biotech subsidiary and the cited ~$253 million patent valuation are management's estimate, not a transaction, and the filing states the subsidiary has had no operational activity to date.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PKTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $123.6K. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PKTX - Latest Insights

PKTX
Sep 03, 2026, 5:16 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.0002
Real-time Price: $0.0020 info
Change: +$0.0018 (+900%) info
Market Cap: $824.26K info
PKTX
Jun 17, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0052
Real-time Price: $0.0020 info
Change: -$0.0032 (-62%) info
Market Cap: $824.26K info